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ABSTRACT
Case report with the aim to characterize the benefits of botulinum toxin injection into salivary glands in association with swallowing 
therapy in patients with severe dysphagia. The medical records of five neurological patients (four male and one female, aged between 
17 and 70 years) who exclusively used alternative feeding were analyzed. Four patients were tracheostomized. Inclusion criterion was 
to present severe dysphagia associated to clinical manifestations of drooling and/or sialorrhea with significant aspiration of saliva, 
restricting the improvement in swallowing rehabilitation. Data were collected before and after intervention associated with botulinum 
toxin injection, regarding the following aspects: mobility and strength of oropharyngeal structures (lips, tongue and cheeks), laryngeal 
elevation, severity degree of dysphagia, use of alternative tube feeding and tracheostomy. After swallowing therapy, four patients 
showed improvement in mobility and strength of the lips, tongue, cheeks and larynx. Four patients presented functional swallowing 
and one of them modified had the severity degree of dysphagia changed. Therefore, most patients were able to receive exclusive oral 
feeding, and only one remained on combination of gastrostomy and oral feeding with pasty consistence. All tracheostomized patients 
had the tracheostomy cannula removed. The study showed that the treatment described contributed to swallowing rehabilitation, 
reintroduction of oral feeding, and withdrawal of the tracheostomy cannula.
Keywords: Deglutition disorders/rehabilitation; Botulinum toxins, type A/therapeutic use; Rehabilitation; Saliva/drug effects; Salivary 
glands; Case studies
INTRODUCTION
Sialorrhea can be caused by abnormal sensitivity and/
or oral motor function due to neuromuscular dysfunction. In 
children and adult population, excessive salivation can occur 
in cases of mental retardation, cerebral palsy, Parkinson’s di-
sease, stroke, central nervous system tumor (CNS TU), head 
and neck post-surgery, amyotrophic lateral sclerosis, and other 
neurological diseases(1-6).
Sialorrhea followed by drooling or stasis of saliva in the 
oral cavity is a clinical sign of swallowing disorder. This factor 
is socially unpleasant(7) and frequently limits the performance 
of swallowing rehabilitation. Drooling and sialorrhea can make 
some exercises proposed during the swallowing rehabilitation 
difficult to perform. In addition, individuals who use plastic 
tracheostomy tube with cuff may present discomfort to deflate 
it, restricting the realization of vocal exercises of laryngeal 
closure to optimize the lower airway mechanism of protection 
and laryngeal elevation.
Treatments to sialorrhea can be conservative (postural 
changes, biofeedback) or non-conservative as the use of anti-
cholinergic drugs, antiparkinsonian drugs, surgical treatment 
of salivary ducts or glands, radiotherapy and application of 
botulinum toxin type A into the salivary glands(3). Botulinum 
toxin type A has been used in the salivary glands of patients 
with residue of saliva in the oral cavity and / or pharyngeal 
recesses, in order to reduce the risk of aspiration and improve 
the quality of life(1,2,4,6,8).
The swallowing rehabilitation associated with botulinum 
toxin in the treatment of oropharyngeal dysphagia has been 
described in literature as a beneficial treatment. It is characteri-
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zed by oropharyngeal muscles exercises and postural changes 
which improve the swallowing mechanism(3,9,10).
Authors(11) performed a study of patients with Parkinson’s 
disease, evaluating the efficiency of swallowing rehabilitation 
associated with botulinum toxin to reduce saliva in the oral 
cavity. The program of swallowing therapy was designed to 
make the patient train to control the frequency of swallowing 
saliva. The results showed reduction of the sialorrhea and the 
authors concluded that the speech pathologist can help in this 
situation, making the act of swallowing conscious and incre-
asing the frequency of swallowing.
Other authors(12) reported the experience of many professio-
nals who have developed a work at a Pediatric Rehabilitation 
Center with 1487 children in order to decrease sialorrhea. A 
great number of treatments have been proposed such as swallo-
wing therapy, medication, surgery of salivary glands and ducts 
or botulinum toxin injection. The authors have observed that 
the swallowing rehabilitation was essential when associated 
with other treatments.
Despite the importance of studies reporting the association 
of treatments, there is still a lack of accurate description in 
literature of what the changes in swallowing are. Thus, this 
study aimed to characterize the benefits of botulinum toxin 
injection associated with swallowing therapy in patients with 
severe dysphagia.
CLINICAL CASE PRESENTATION
This study was reviewed and approved by the Research 
Ethics Committee of the Universidade Federal de São Paulo, 
number 1003/10. Since the research was retrospective and did 
not have direct contact with the patient, there was no need to 
use the Free and Informed Consent Term.
Retrospective study of medical records of patients eva-
luated and treated at the Dysphagia Ambulatory and at the 
Pediatric Oncology Institute. The inclusion criteria were 
patients with severe, i.e., with clinical manifestations such as 
drooling and/or sialorrhea with aspiration of saliva, restricting 
the improvement of swallowing therapy. All patients were 
subjected to swallowing therapy associated with botulinum 
toxin injection.
Initially, data collected were the identification of each pa-
tient. As for the clinical assessment of swallowing, data were 
collected before and after swallowing therapy associated with 
botulinum toxin, based on mobility and strength of oropha-
ryngeal structures (lips, tongue, cheeks), laryngeal elevation, 
dysphagia severity degree, use of alternative tube feeding and 
tracheostomy.
It is noteworthy that, for all patients analyzed, swallowing 
therapy started after the botulinum toxin, ranging from three to 
seven days, according to the patient’s clinical conditions and 
beginning of ambulatory treatment. The dose injected in the 
submandibular and parotid glands were 20 and 40 units (U).
The five neurological patients had the following diagnoses: 
tumor of the central nervous system characterized by bulb tip 
lesion (two patients), Parkinson’s disease (one patient), stroke 
(one patient) and polyneuropathy of critically ill patients (one 
patient). All of them were using exclusively alternative tube 
feeding for over three months (nasogastric tube or gastros-
tomy). Four patients were tracheostomized without mechanical 
ventilation. Three of them used a plastic cannula with cuff 
inflated and one used a metallic cannula.
In clinical assessment before swallowing therapy, all 
patients had disorders in mobility and strength of the lips, 
tongue and cheeks. Patients were not able to make movements 
with amplitude, accuracy and coordination of lips, tongue and 
cheeks. As for strength, the patients could not use it against 
the motion proposed by the speech pathologist, which shows 
subjectively reduction of the tonus. After therapy an improve-
ment of these features was observed (Table 1). 
Concerning dysphagia severity degree, all patients had 
severe dysphagia before therapy. After treatment, there was 
a recovery of functional swallowing in most cases. As for 
nutrition and hydration, all patients were using exclusive al-
ternative tube feeding before therapy. After therapy, most of 
the patients reestablished exclusive oral feeding. Initially, most 
of the patients used tracheostomy and after therapy all patients 
restored oronasal breathing, with decannulation (Table 1). 
The swallowing therapy lasted for three to twelve months, 
according to the case. The improvement was gradual. In the be-
ginning, the patient should be able to swallow saliva with safe. 
After it the swallowing training with food was started. When 
the patient could swallow food trained during swallowing 
therapy without presenting any clinical signs of supraglottic 
penetration an/or tracheal aspiration, such consistency was 
released for oral feeding.
DISCUSSION
The main objective of swallowing rehabilitation is to res-
tore the swallowing of saliva and reintroduce the oral feeding 
safely when possible(13). In this study, it was observed that 
the sample consisted of critically ill patients with severe dys-
Table 1. Distribution of the variables studied before and after swallowing 
therapy associated with botulinum toxin 
Variables Pre Post
Dysphagia 
severity degree
Severe dysphagia 4 0
Moderate dysphagia 1 1
Mild dysphagia 0 0
Functional swallow 0 4
Alteration of OMO Mobility and strength 5 1
Adequate OMO Mobility and strength 0 4
Feeding mode
Nasogastric tube 2 0
PEG 3 0
Total oral intake 0 4
Partial OF + PEG 0 1
Tracheostomy
Plastic with cuff 3 0
Metallic 1 0
Without 1 5
Note: OMO = oral myofunctional organs; PEG = percutaneous endoscopic 
gastrostomy; OF = oral feeding
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phagia. These patients had a significant difficulty concerning 
swallowing of saliva, with increased risk of pneumonia. The 
botulinum toxin type A in the salivary glands was beneficial in 
this sample, allowing a reduction in the accumulation of saliva 
in the oral cavity and pharyngeal recesses and later onset of 
swallowing therapy. 
After application of botulinum toxin injection, the swallo-
wing therapy occurred weekly and consisted of myofunctional 
and vocal exercises to help glottal closure, laryngeal elevation 
and anteriorization. The indirect therapies (without food) 
and direct (with food) were selected according to the needs 
of each case(13). Swallowing therapy aimed to coordinate the 
oral and pharyngeal phases of swallowing and reintroduce 
oral feeding safely.
As soon as the patients were able to manipulate and 
swallow the saliva without risk of aspiration, it was possible 
to verify whether they felt comfortable to stay with the cuff 
deflated or not. When this stage was reached, the time spent 
with deflated cuff was gradually increased. Thus, it was pos-
sible to make the digital occlusion of the tracheostomy tube 
and perform vocal exercises to glottal closure and laryngeal 
elevation, in order to protect the lower airways. Considering 
our sample, four patients improved mobility and strength of 
the lips, tongue, cheeks and larynx (Table 1).
The techniques have allowed the improvement of swallowing 
saliva, and then direct therapy was initiated, i.e., the training of 
swallowing with controlled volume of food. The first consis-
tence used was pasty, to provide better oral control(13,14). After 
satisfactory performance, the volume was increased and the 
consistency was modified to thickened liquid, thin liquid, semi 
solid and solid respectively. Four patients had the swallowing 
rehabilitated after swallowing therapy (functional swallowing) 
and one patient has changed the dysphagia severity degree from 
severe to moderate (Table 1). Thus, most of the patients were 
able to receive exclusive oral feeding and one remained on a 
combination of gastrostomy and pasty oral feeding (Table 1).
Another benefit achieved with swallowing therapy was 
the decannulation. In this study, four patients were using 
tracheostomy before therapy, After the swallowing therapy 
associated with botulinum toxin injection, all patients had the 
tracheostomy tube removed and occlusion of the tracheos-
tomy (Table 1). Additionally, it was possible to establish oral 
communication providing the patient’s participation during 
the therapeutic process, and ensuring their rehabilitation and 
improving quality of life.
In our study follow-up time ranged from three to 12 mon-
ths. This variation is justified by different diseases, clinical sta-
tus, dysphagia severity degree and therapy frequency. Another 
aspect observed during the treatment was the improvement in 
swallowing function during the effect of botulinum toxin. A 
single injection of the drug was enough for the four patients 
to have conditions for participating of the swallowing thera-
py and reintroduction of oral feeding. Only one patient who 
had degenerative neurological disease (Parkinson’s Disease) 
required additional injection. Perhaps the combination of the 
two treatments may have avoided the additional injection of 
the drug in question and, therefore, further studies are needed. 
Several authors have reported that the effect of botulinum 
toxin can vary from a period of three to seven months(2,4,6,15).
Considering the results, we observed that the combina-
tion of the two treatments allowed the improvement of the 
swallowing of the patients. Thus, it is extremely important that 
the speech pathologist is aware of treatment alternatives for 
the reduction of sialorrhea, in order to integrate swallowing 
therapy to the treatment. This treatment option improves safe 
swallowing, prevent pneumonia, malnutrition and dehydration. 
FINAL COMMENTS
The benefits of botulinum toxin type A associated with 
swallowing therapy in patients with severe dysphagia are: re-
duction of the sialorrhea; improvement of mobility and strength 
of oropharyngeal structures; rehabilitation of swallowing; 
reintroduction of oral food and decannulation.
RESUMO
Estudo de casos para caracterizar os benefícios da aplicação de toxina botulínica em glândulas salivares, associada à fonoterapia em 
pacientes disfágicos graves. Foram analisados cinco prontuários de pacientes neurológicos, em uso exclusivo de via alternativa de 
alimentação, com idades entre 17 e 70 anos, sendo quatro do gênero masculino e um do gênero feminino. Do total, quatro pacientes 
eram traqueostomizados. Foi considerado como critério de inclusão apresentar disfagia grave, com manifestações clínicas de escape 
extra oral e/ou acúmulo de saliva em cavidade oral e aspiração traqueal maciça de saliva, com limitação da fonoterapia. Quanto à 
avaliação clínica da deglutição, foram coletados dados pré e pós-fonoterapia associada à aplicação de toxina botulínica, quanto aos 
seguintes aspectos: mobilidade e força das estruturas orofaríngeas (lábios, língua, bochechas), elevação laríngea, grau da disfagia, 
uso de via alternativa de alimentação e traqueostomia. Quanto aos resultados pós- fonoterapia foi observado, em quatro pacientes, 
melhora da mobilidade e força de lábios, língua, bochechas e laringe. Quatro pacientes apresentaram deglutição funcional e um teve 
modificação do grau de gravidade da disfagia. Desta forma, a maioria foi capaz de receber dieta exclusiva por via oral e apenas um 
permaneceu com dieta mista, ou seja, gastrostomia e dieta via oral na consistência pastosa. Todos os pacientes traqueostomizados 
tiveram a cânula de traqueostomia removida. O estudo mostrou que o tratamento descrito acima contribui para a reabilitação da 
deglutição, reintrodução de alimentos por via oral e retirada da cânula de traqueostomia. 
Descritores: Transtornos de deglutição/reabilitação; Toxinas botulínicas tipo A/uso terapêutico; Saliva/efeitos de drogas; Glândulas 
salivares; Estudos de casos
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